DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/339ec3/lung_transplantati) has announced the addition of Global Markets Direct's new report "Lung Transplantation - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Lung Transplantation - Pipeline Review, H1 2012', provides an overview of the Lung Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. 'Lung Transplantation - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Key Topics Covered: Introduction
Global Markets Direct Report Coverage
Lung Transplantation Overview
Therapeutics Development
An Overview of Pipeline Products for Lung Transplantation
Lung Transplantation Therapeutics under Development by Companies
Lung Transplantation Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Lung Transplantation Therapeutics - Products under Development by Companies
Lung Transplantation Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Lung Transplantation Therapeutics Development
Lung Transplantation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lung Transplantation Therapeutics - Drug Profile Updates
Lung Transplantation Therapeutics - Dormant Products
Lung Transplantation - Product Development Milestones
Featured News & Press Releases
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
Feb 24, 2010: APT Pharmaceuticals Completed Enrollment in Phase III for Inhaled Cyclosporine
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Companies Mentioned:
- Quark Pharmaceuticals, Inc.
- Vectura Group plc
- Novartis AG
- PARI Pharma GmbH
- APT Pharmaceuticals, Inc.
- Fresenius Biotech GmbH
For more information visit http://www.researchandmarkets.com/research/339ec3/lung_transplantati